The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

NCT05361031 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Helixmith Co., Ltd.